Jefferies Financial Group’s PTC Therapeutics PTCT Stock Holding History

Jefferies Financial Group’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$92.3M	Sell	1,354,459 -304,022	-18%	-$21.5M	0.63%	18
2025 Q4	$126M	Buy	1,658,481 +73,803	+5%	+$5.36M	0.64%	22
2025 Q3	$97.3M	Buy	+1,584,678	New	+$82.5M	0.46%	27
2024 Q4	–	Sell	-522,895	Closed	-$19.4M	–	1795
2024 Q3	$19.4M	Hold	522,895	–	–	0.14%	96
2024 Q2	$16M	Buy	522,895 +250,000	+92%	+$8.1M	0.17%	98
2024 Q1	$7.94M	Sell	272,895 -4,000	-1%	-$112K	0.07%	200
2023 Q4	$7.63M	Buy	276,895 +8,760	+3%	+$200K	0.05%	286
2023 Q3	$6.01M	Buy	268,135 +240	+0.1%	+$8.93K	0.05%	292
2023 Q2	$10.9M	Buy	267,895 +252,095	+1,596%	+$12.3M	0.1%	182
2023 Q1	$765K	Buy	+15,800	New	+$722K	0.01%	979

Other funds holding PTCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Financial Group's PTCT Position: Q1 2026 in Review

Jefferies Financial Group reduced its PTC Therapeutics (PTCT) stake by 18% in Q1 2026, selling an estimated $21.5M and leaving 1,354,459 shares worth $92.3M. The position accounts for 0.63% of the portfolio, ranked #18.

Jefferies Financial Group first reported a position in PTCT in Q1 2023 and has held it in 10 quarters since. The position peaked at $126M in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

Jefferies Financial Group held 1,354,459 shares of PTC Therapeutics worth $92.3M as of Q1 2026.
Jefferies Financial Group sold 304,022 PTC Therapeutics shares in Q1 2026, an estimated $21.5M.
PTC Therapeutics made up 0.63% of Jefferies Financial Group's portfolio in Q1 2026, its #18 holding.
Jefferies Financial Group first reported a position in PTC Therapeutics in Q1 2023 and has held it in 10 quarters since.
Jefferies Financial Group's PTC Therapeutics position peaked at $126M in Q4 2025.
349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.